Table 4.
Overall survival analysis in patient subgroups according to BIM deletion status
| Subgroup | Number of patients | Number of events (%)
|
Hazard ratio (95% CI) |
|
|---|---|---|---|---|
| Heterozygous | Wild type | |||
| Overall | 140 | 24 (64.9) | 54 (52.4) | 1.14 (0.70–1.84) |
| Age (years) | ||||
| ≤65 | 103 | 17 (60.7) | 38 (50.7) | 1.18 (0.66–2.09) |
| >65 | 37 | 7 (77.8) | 16 (57.1) | 0.94 (0.38–2.32) |
| Gender | ||||
| Male | 46 | 5 (62.5) | 25 (65.8) | 0.59 (0.22–1.57) |
| Female | 94 | 19 (65.5) | 29 (44.6) | 1.64 (0.91–2.95) |
| Smoking | ||||
| No | 106 | 20 (66.7) | 36 (47.4) | 1.52 (0.87–2.63) |
| Yes | 34 | 4 (57.1) | 18 (66.7) | 0.50 (0.16–1.50) |
| EGFR mutation | ||||
| Exon 19 | 73 | 14 (63.6) | 21 (41.2) | 1.49 (0.76–2.93) |
| Exon 21 | 59 | 8 (66.7) | 30 (63.8) | 0.87 (0.40–1.91) |
| Others | 8 | 2 (66.7) | 3 (60.0) | 1.21 (0.16–9.34) |
| Prior chemotherapy | ||||
| No | 39 | 6 (85.7) | 18 (56.3) | 1.44 (0.57–3.67) |
| Yes | 101 | 18 (60.0) | 36 (50.7) | 1.06 (0.60–1.86) |
| EGFR-TKIs treatment | ||||
| First line | 54 | 10 (83.3) | 24 (57.1) | 1.56 (0.74–3.28) |
| Second or more line | 86 | 14 (56.0) | 30 (49.2) | 0.98 (0.52–1.86) |
Abbreviations: CI, confidence interval; EGFR, epidermal growth factor receptor; TKIs, tyrosine kinase inhibitors.